Kim Chi, MD, FRCPC, discusses the rationale and design of the phase 3 KLK2-comPAS trial evaluating pasritamig alone and in combination with JNJ-9401 in patients with mCRPC.
Opinion|Videos|November 14, 2025
Stacy Loeb, MD, highlights long-term data on PSA screening
Author(s)Stacy Loeb, MD, MSc, PhD (Hon)
Fact checked by: Hannah Clarke
Stacy Loeb, MD, discussed key takeaways from the European Randomized Study of Screening for Prostate Cancer.
Advertisement
In a recent interview with Urology Times®, Stacy Loeb, MD, discussed key takeaways from the European Randomized Study of Screening for Prostate Cancer (ERSPC). Loeb is a urologists at NYU Langone Health in New York, New York.
Advertisement
Related to this article
Jeffrey M. Spier, MD, reviews evidence on ARPI dose reduction in prostate cancer and discusses monitoring treatment response, tolerability, and dose reescalation.
Jeffrey M. Spier, MD, discusses managing ARPI-related fatigue through dose adjustments, patient monitoring, and strategies to maintain treatment adherence.
Jack R. Andrews, MD, discusses BED-PSMA-411 findings comparing PSMA-PET detection rates and urinary excretion in prostate cancer biochemical recurrence.
Abraham Morgentaler, MD, reviews evidence showing no association between testosterone therapy and prostate cancer risk and explains the saturation model of androgen action.
The phase 1/2 CELC-G-201 study found preliminary antitumor activity and manageable toxicity with gedatolisib plus darolutamide in metastatic castration-resistant prostate cancer.
Longer-term findings from the phase 2 ARACOG study suggest differences in objectively measured cognitive function between ARPIs.
Engy Habashy, MD, discusses key takeaways from the 2025 AUA GSM guideline, including the role of androgens and hormonal therapies in managing genitourinary syndrome of menopause.
Advertisement
Advertisement
Trending on Urology Times
1
ESMO 2026: Key presentations across genitourinary oncology
2
How PSMA-PET shapes staging and recurrence workup in prostate cancer
3
Darolutamide associated with less cognitive change than enzalutamide in prostate cancer
4
European Commission approves perioperative pembrolizumab plus enfortumab vedotin for MIBC
5